A new trading day began on Tuesday, with Syndax Pharmaceuticals Inc (NASDAQ: SNDX) stock price down -1.16% from the previous day of trading, before settling in for the closing price of $13.79. SNDX’s price has ranged from $13.26 to $25.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1801.91% over the past five years. Meanwhile, its annual earnings per share averaged -21.37%. With a float of $81.08 million, this company’s outstanding shares have now reached $85.57 million.
Let’s look at the performance matrix of the company that is accounted for 184 employees. In terms of profitability, gross margin is -169.78%, operating margin of -1942.5%, and the pretax margin is -1796.46%.
Syndax Pharmaceuticals Inc (SNDX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Syndax Pharmaceuticals Inc is 5.02%, while institutional ownership is 100.30%. The most recent insider transaction that took place on Jun 14 ’24, was worth 25,037. In this transaction Chief Financial Officer of this company bought 1,250 shares at a rate of $20.03, taking the stock ownership to the 52,623 shares.
Syndax Pharmaceuticals Inc (SNDX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.50% during the next five years compared to -0.41% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Here are Syndax Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 72.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.63, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -3.76 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) saw its 5-day average volume 2.53 million, a positive change from its year-to-date volume of 1.21 million. As of the previous 9 days, the stock’s Stochastic %D was 13.12%. Additionally, its Average True Range was 0.93.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 3.66%, which indicates a significant decrease from 9.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.25% in the past 14 days, which was lower than the 64.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.66, while its 200-day Moving Average is $20.17. Nevertheless, the first resistance level for the watch stands at $13.93 in the near term. At $14.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.51. If the price goes on to break the first support level at $13.35, it is likely to go to the next support level at $13.06. Assuming the price breaks the second support level, the third support level stands at $12.77.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
With a market capitalization of 1.16 billion, the company has a total of 85,358K Shares Outstanding. Currently, annual sales are 0 K while annual income is -209,360 K. The company’s previous quarter sales were 12,500 K while its latest quarter income was -84,130 K.
